source
- Trump's Department of War bets $47M on Flagship biotechs to develop countermeasuresThe Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.
- Viking Therapeutics’ VK2735 shows 17.7% weight loss in Phase 1 and maintains effect with less frequent dosingViking Therapeutics reported Phase 1 results for its injectable GLP-1/GIP dual agonist VK2735, showing an average 17.7% reduction in body weight after 21 weeks of weekly dosing in a placebo-control…